Initial effects of the national PCV7 childhood immunization program on adult invasive pneumococcal disease in israel

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Regev Yochay, Gili ^a   Rahav, Galia ^a   Riesenberg, Klaris ^b   Wiener Well, Yonit ^c   Strahilevitz, Jacob ^d   Stein, Michal ^e   Glikman, Daniel ^f   Weber, Gabriel ^g   Potasman, Israel ^h   Dagan, Ron ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e WOLFSON MEDICAL CENTER   (Israel)

^f WESTERN GALILEE HOSPITAL   (Israel)

^g CARMEL MEDICAL CENTER   (Israel)

^h BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD CULTURE; CEREBROSPINAL FLUID; CHILD; COMORBIDITY; CONTROLLED STUDY; FATALITY; GROUPS BY AGE; HUMAN; INCIDENCE; ISRAEL; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PNEUMOCOCCAL INFECTION; RISK FACTOR; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION; ADULT; CLASSIFICATION; EVALUATION STUDY; FEMALE; HEALTH SURVEY; ISOLATION AND PURIFICATION; MALE; PNEUMOCOCCAL INFECTIONS; PREVENTIVE HEALTH SERVICE;

ADULT; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; ISRAEL; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 84895739496     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088406     Document Type: Article

References (34)

1. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, et al. (2013) Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 8: e60273.
2. Melegaro A, Edmunds WJ (2004) The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 19: 353-363. (Pubitemid 39005435)
3. Cadeddu C, De Waure C, Gualano MR, Di Nardo F, Ricciardi W (2012) 23-valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: is it really effective? J Prev Med Hyg 53: 101-103.
4. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32-41.
5. Ardanuy C, Tubau F, Pallares R, Calatayud L, Dominguez MA, et al. (2009) Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 48: 57-64.
6. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, et al. (2009) Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 49: 205-212.
7. Chibuk TK, Robinson JL, Hartfield DS (2010) Pediatric complicated pneumonia and pneumococcal serotype replacement: trends in hospitalized children pre and post introduction of routine vaccination with Pneumococcal Conjugate Vaccine (PCV7). Eur J Pediatr 169: 1123-1128.
8. Rose M, Zielen S (2009) Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines 8: 1351-1364.
9. Isaacman DJ, McIntosh ED, Reinert RR (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14: e197-209.
10. van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Keijzers WC, et al. (2010) Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 304: 1099-1106.
11. Williams SR, Mernagh PJ, Lee MH, Tan JT (2011) Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust 194: 116-120.
12. Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, et al. (2005) Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 41: 21-29. (Pubitemid 40863739)
13. Fedson DS, Guppy MJ (2013) Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum Vaccin Immunother 9.
14. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, et al. (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294: 2043-2051. (Pubitemid 41539937)
15. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, et al. (2006) Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 25: 250-254. (Pubitemid 43379067)
16. Kendall BA, Dascomb KK, Mehta RR, Mason EO, Ampofo K, et al. (2011) Streptococcus pneumoniae serotypes in Utah adults at the end of the PCV7 era. Vaccine 29: 9123-9126.
17. van Hoek AJ, Andrews N, Waight PA, George R, Miller E (2012) Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One 7: e39150.
18. Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, et al. (2012) Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine 30: 6600-6607.
19. Regev-Yochay G, Rahav G, Strahilevitz J, Bishara J, Katzir M, et al. (2013) A nationwide surveillance of invasive pneumococcal disease in adults in Israel before an expected effect of PCV7. Vaccine 31: 2387-2394.
20. Tyrrell GJ, Lovgren M, Ibrahim Q, Garg S, Chui L, et al. (2012) Epidemic of invasive pneumococcal disease, western Canada, 2005-2009. Emerg Infect Dis 18: 733-740.
21. Balicer RD, Zarka S, Levine H, Klement E, Sela T, et al. (2010) Control of Streptococcus pneumoniae serotype 5 epidemic of severe pneumonia among young army recruits by mass antibiotic treatment and vaccination. Vaccine 28: 5591-5596.
22. Liesenborghs L, Verhaegen J, Peetermans WE, Vandeven J, Flamaing J (2013) Trends in serotype prevalence in invasive pneumococcal disease before and after infant pneumococcal vaccination in Belgium, 2002-2010. Vaccine 31: 1529-1534.
23. Fleming-Dutra KE, Taylor T, Link-Gelles R, Garg S, Jhung MA, et al. (2013) Effect of the 2009 influenza A(H1N1) pandemic on invasive pneumococcal pneumonia. J Infect Dis 207: 1135-1143.
24. Lee BE, Mukhi SN, Drews SJ (2010) Association between patient age and influenza A subtype during influenza outbreaks. Infect Control Hosp Epidemiol 31: 535-537.
25. Weinberger DM, Harboe ZB, Viboud C, Krause TG, Miller M, et al. (2013) Pneumococcal disease seasonality: incidence, severity, and the role of influenza activity. Eur Respir J.
26. Shrestha S, Foxman B, Weinberger DM, Steiner C, Viboud C, et al. (2013) Identifying the interaction between influenza and pneumococcal pneumonia using incidence data. Sci Transl Med 5: 191ra184.
27. Dos Santos SR, Passadore LF, Takagi EH, Fujii CM, Yoshioka CR, et al. (2013) Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation. Vaccine.
28. Maraki S, Samonis G, Galanakis E (2010) Serotypes and susceptibilities of paediatric clinical isolates of Streptococcus pneumoniae in Crete, Greece, before and after the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 29: 1449-1451.
29. Vestrheim DF, Hoiby EA, Aaberge IS, Caugant DA (2010) Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 17: 325-334.
30. Tyrrell GJ, Lovgren M, Chui N, Minion J, Garg S, et al. (2009) Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine 27: 3553-3560.
31. Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, et al. (2013) Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet 45: 656-663.
32. Gertz RE, Jr., Li Z, Pimenta FC, Jackson D, Juni BA, et al. (2010) Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 201: 770-775.
33. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, et al. (2005) Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116: e408-413. (Pubitemid 44336655)
34. Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D, et al. (2007) Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 195: 347-352. (Pubitemid 46146111)